Position Paper: Immunotherapy

Allergy

Volumn 48, Issue , 1993, Pages 9-35

  Mailing, H J ^a   Weeke, B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALLPYRAL; ANTIALLERGIC AGENT; ANTISERUM; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; POLLEN EXTRACT; POLLINEX; UNCLASSIFIED DRUG;

ALLERGY; ASTHMA; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW;

EID: 0027214706     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1993.tb04754.x     Document Type: Article

References (206)

1. Adequate clinical trials of immunotherapy
2. Sublingual therapy for allergic rhinitis
3. Anaphylactic reaction to de‐sensitisation
4. Personnel and equipment to treat systemic reactions caused by immu‐notherapy with allergenic extracts
5. Report on behalf of International Union of Immunologic Societies (IUIS)
6. Rush immunotherapy with a standardized Bermuda grass pollen extract
7. Baker's asthma: prevalence and evaluation of immunotherapy with a wheat flour extract
8. Fatal asthma
9. Histo‐pathological examinations of local granulomas during specific hyposensitization
10. Reduction of side effects from rush‐immunotherapy with honeybee venom by pretreatment with terfenadine
11. Immunoregulatory function of specific IgG. II. Clinical evaluation of combined active and passive immunotherapy
12. Immunotherapy with dog and cat extracts in children
13. Evaluation of immunotherapy‐induced changes in specific IgE, IgG and IgG subclasses in birch pollen allergic patients by means of immunoblotting. Correlation with clinical response
14. Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract
15. Dewdney JM
16. Specific immunotherapy in asthma
17. Double‐blind, placebo‐controlled immunotherapy with mixed grass‐pollen allergoids. II. Comparison between parameters assessing efficacy of immunotherapy
18. Specific immunotherapy with a standardized Dermatophagoides pter‐onyssinus extract. II. Prediction of efficacy of immunotherapy
19. Specific immunotherapy with a standardized Dermatophagoides pter‐onyssinus extract. III. Systemic reactions during the rush protocol in patients suffering from asthma
20. Double‐blind, placebo‐controlled immunotherapy with mixed grass‐pollen allergoids. III. Efficacy and safety of unfractionated and high‐molecular‐weight preparations in rhinoconjunctivitis and asthma
21. Double‐blind, placebo‐controlled immunotherapy with mixed grass‐polleri allergoids. IV. Comparison of the safety and efficacy of two dosages of a high‐molecular‐weight allergoid
22. Assessment and clinical relevance of eosinophil inflammation in asthma
23. Specific immunotherapy in asthma
24. Microscopic anatomy of bronchial asthma and its implications regarding pathogenesis
25. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple‐pollen species. II. Efficacy of a double‐blind, placebo‐controlled, specific immunotherapy with standardized extracts
26. Allergic rhinitis to ragweed pollen. I. Reassessment of the effects of immunotherapy on cellular and humoral responses
27. Allergic rhinitis to ragweed pollen. II. Modulation of histamine‐releasing factor production by specific immunotherapy
28. Immunotherapy with dog and cat allergen preparations in dog‐sensitive and cat‐sensitive asthmatics
29. Detection of human auto‐anti‐idiotypic antibodies (Ab2). II. Generation of Ab2 in atopic patients undergoing allergen immunotherapy
30. Use of nonstimulatory peptides: a new strategy for immunotherapy?
31. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen‐induced early asthmatic response, late asthmatic response, and increased bronchial responsiveness to histamine
32. CSM update: desensitising vaccines
33. A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children
34. Mechanisms of glucocorticoid action in asthma: too little, too late
35. American Medical Association, December 1986
36. A double‐blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac®) in patients with perennial rhinitis. I. Clinical aspects
37. Nasal challenge with ragweed pollen in hay fever patients
38. Immunotherapy with allergens
39. Local immunotherapy with Dermatophagoides extract in asthma
40. Hyposensitization of patients with allergic rhinitis by intranasal administration of chemically modified grass pollen allergen. A pilot study
41. The subclass nature and clinical significance of the IgG antibody response in patients undergoing allergen‐specific immunotherapy
42. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens
43. A double‐blind, multicenter immunotherapy trial in children using a purified and standardized Cladosporium herbarum preparation. I. Clinical results
44. Immunotherapy (hyposensitization) and bronchial asthma
45. Skin tests used in type I allergy testing. Position Paper
46. Immunotherapy with monomethoxypolyethylene glycol modified allergens
47. Allergen standardization and skin tests. Position Paper
48. Hyposensitization with Dermatophagoides pteronyssinus in house dust allergy: a controlled study of clinical and immunological effects
49. Immunotherapy and allergic inflammation
50. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite
51. Allergen immunotherapy
52. Allergy to penicillin
53. Selective suppression of antibody production with the aid of radiolabeled birch pollen allergen
54. Prognosis for bronchial asthma arising in infancy after nonspecific treatment hitherto applied
55. Suppression of the late cutaneous response by immunotherapy
56. Anaphylactic reaction to desensitisation
57. Persistent subcutaneous nodules in children hyposensitized with aluminium‐containing allergen extracts
58. Clinical effects of hyposensitization using a purified allergen preparation from timothy pollen as compared to crude aqueous extracts from timothy pollen and a four‐grass pollen mixture respectively
59. Immunotherapy decreases antigen‐induced eosinophil cell migration into the nasal cavity
60. Use of IgE‐derived peptides to treat allergy
61. Local intranasal immunotherapy with high‐dose polymerized ragweed extract
62. A review of controversial diagnostic and therapeutic techniques employed in allergy
63. Modified forms of allergen immunotherapy
64. Does immunotherapy have a role in the treatment of asthma?
65. Late and immediate systemic‐allergic reactions to inhalant allergen immunotherapy
66. New experimental approaches to the therapy of atopic diseases
67. Comparison of the in vivo and in vitro response to ragweed immunotherapy in children and adults with ragweed‐induced rhinitis
68. Immunotherapy with a standardized Dermatophagoides pter‐onyssinus extract. IV. Systemic reactions according to the immunotherapy schedule
69. Risk of systemic reactions in patients taking beta‐blocker drugs receiving allergen immunotherapy injections
70. Contribution of inflammatory mediators to the immediate asthmatic reaction
71. Oral hyposensitization with enteric‐coated allergens as extension therapy following a basic subcutaneous course of injections
72. The Vienna challenge chamber—a new method of exposure tests
73. Double‐blind, placebo‐controlled rush immunotherapy with a standardized Ahemaria extract
74. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells
75. Use of glutaraldehyde‐modified timothy grass pollen extract in nasal hyposensitization treatment of hay fever
76. A study of the natural history of bronchial asthma in children
77. The value of hyposensitization therapy for bronchial asthma in children—a 14‐year study
78. Some aspects of the natural history of asthma
79. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen‐injection therapy (Pollinex‐R) in the treatment of seasonal allergic rhi‐noconjunctivitis
80. Polyethylene glycol‐modified ragweed pollen extract in rhinocon‐junctivitis
81. The hazard of mould hyposensitization in children with asthma
82. Hypotheses on the contribution of late‐phase allergic responses to the understanding and treatment of allergic diseases
83. The mechanisms of glucocorticosteroid action in asthma
84. Treatment of allergic rhinitis in the 1990s
85. Regulation of the IgE system: experimental and clinical aspects
86. Asthma and inflammation
87. Clinical and immunologic follow‐up of patients who stop venom immunotherapy
88. The effect of pre‐seasonal immunotherapy on the production of histamine‐releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double‐blind, placebo‐controlled, randomized study
89. The effect of aerosol distribution on airway responsiveness to inhaled meth‐acholine in patients with asthma
90. Rates of release of subcutaneously injected antigens in the rat
91. A double‐blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to the pollen allergen and serum‐specific IgE antibody
92. Evaluation of the adverse effects of long‐term hyposensitization
93. Histamine‐releasing factors and IgE heterogeneity
94. Immunotherapy with cat‐ and dog‐dander extracts. IV. Effects of 2 years of treatment
95. Regulation of the human immune response to ragweed pollen by immunotherapy. A controlled trial comparing the effect of immunosuppressive peptic fragments of short ragweed with standard treatment
96. Fatalities from immunotherapy (IT) and skin testing (ST)
97. Morphological studies on bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids
98. Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen‐antibody complexes
99. Allergen‐antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients
100. Equivalent reaction using skin prick test and intradermal test
101. Clustered immunotherapy with yellow jacket venom. Evaluation of the influence of time interval on in vivo and in vitro parameters
102. Diagnosis and immunotherapy of mould allergy. III. Diagnosis of Cladosporium allergy by means of symptom score, bronchial provocation test, skin prick test, RAST, CRIE and histamine release
103. Diagnosis and immunotherapy of mould allergy. IV. Relation between asthma symptoms, spore counts and diagnostic tests
104. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy wit
105. Diagnosis and immunotherapy of mould allergy. VI. IgE‐mediated parameters during a one‐year placebo‐controlled study of immunotherapy wit
106. Diagnosis and immunotherapy of mould allergy. VII. IgG subclass response and relation to the clinical efficacy of immunotherapy wit
107. Diagnosis and immunotherapy of mould allergy. VIII. Qualitative and quantitative estimation of IgE in Cladosporium immunotherapy
108. EAACI Immunotherapy Position Paper
109. Clinical efficacy of allergen immunotherapy
110. New ideas in allergen‐specific immunotherapy
111. Allergen nomenclature
112. The natural history of childhood asthma to adult life
113. Reduction of increased serum neutrophil chemotactic activity following effective hyposensitization in house dust mite allergy
114. A placebo‐controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen‐specific IgE, IgG, and IgG subclasses
115. Guidelines for the standardization of bronchial provocation tests with allergens. An update by an international committee
116. Nasal hyposensitization and hay fever
117. The safety of immunotherapy during pregnancy
118. High dose grass pollen tablets used for hyposensitization in hay fever patients. A one‐year double‐blind placebo‐controlled study
119. Does the effect of immunotherapy last after termination of treatment? Follow‐up study in patients with grass pollen rhinitis
120. Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. I. Clinical effect evaluated by diary cards and a retrospective assessment
121. Dust‐free bedrooms in the treatment of asthmatic children with house dust or house dust mite allergy: a controlled trial
122. Immunotherapy with Hymenoptera venoms. Position Paper
123. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy
124. Cross reactivity between trees during immunotherapy. II. Specific IgE and IgG responses
125. Effect of pollen immunotherapy on food hypersensitivity in children with birch pollinosis
126. Inflammatory mediators in late antigen‐induced rhinitis
127. Inflammation and asthma
128. The role of IgG subclass antibodies in the clinical response to immunotherapy in allergic disease
129. Prospective survey of local and systemic reactions to immunotherapy with pollen extracts
130. Local intranasal immunotherapy for ragweed allergic rhinitis. I. Clinical response
131. Maintenance immunotherapy in ragweed hay fever. Booster injections at six‐week intervals
132. The great debate: immunotherapy and asthma
133. Immunotherapy for nasal allergy
134. International units
135. Two‐year study of clinical results after discontinuation of ragweed allergoid immunotherapy
136. Immunotherapy
137. The safety of allergenic immunotherapy
138. Immunotherapy in cat‐induced asthma. Double‐blind trial with evaluation of in vivo and in vitro responses
139. Allergen immunotherapy in asthma: evidence for efficacy
140. The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis
141. A double‐blind study of hyposensitization with an alginate‐conjugated extract of Dermatophagoides pteronyssinus (Conjuvac®) in patients with perennial rhinitis. II. Immunological aspects
142. Immunotherapy
143. Polymerized ragweed antigen E. II. In vivo elimination studies and reactivity with IgE antibody system
144. Effects of one‐year hyposensitization in allergic rhinitis. Comparison of two house dust mite extracts
145. Ragweed IgE and IgG4 antibody in nasal secretions during immunotherapy
146. IgE regulation during immunotherapy of allergic diseases
147. Mechanisms and management of anaphylactic shock not responding to traditional therapy
148. Suppression of late‐phase skin reactions by immunotherapy with ragweed extract
149. Oral immunotherapy: a way forward?
150. ε R2/CD23 expression on T and B lymphocytes during rush hyposensitization
151. Asthma in children. A follow‐up study of 688 patients after an interval of twenty years
152. Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season
153. Extracorporeal hyposensitization
154. Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospective study
155. Quality assurance and standardization of allergy extracts in allergy practice
156. Seasonal nephrotic syndrome. Description and immunological findings
157. Dysregulation of IgE responses and airway allergic inflammation in atopic individuals
158. Marked enhancement of antibody synthesis following immunization with antigen bound to host lymphocytes. A potential treatment of patients with allergy
159. Physician‐reported patient response to immunotherapy: a retrospective study of factors affecting the response
160. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins
161. Continued follow‐up investigation concerning the fate of 298 asthmatic children
162. Long‐term prognosis of juvenile asthma
163. Immunotherapy of pollinosis in children. Investigation of the immunologic basis of clinical improvement
164. Mold‐induced asthma
165. Comparative clinical‐immunological study of oral and subcutaneous immunotherapy in children with extrinsic bronchial asthma
166. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite
167. Allergenic extracts: a review of their safety and efficacy
168. Mortality from asthma
169. The use of β‐agonists and the risk of death and near death from asthma
170. Drug allergy
171. Generation of suppressor cells in atopic patients during immunotherapy that modulate IgE synthesis
172. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double‐blind study
173. Orally administered grass pollen
174. Oral immunotherapy in birch pollen hay fever
175. The current status of allergen immunotherapy (hyposensitisation). Report of WHO/IUIS working group
176. Occurrence of asthma in patients with allergic rhinitis. Prognostic value of clinical and laboratory tests
177. Risk of anaphylaxis in patients receiving beta‐blocker drugs
178. Combination of parenteral and oral immunotherapy in grass pollen allergic children
179. Changes in the levels of house dust mite specific IgG4 during immunotherapy in asthmatic children
180. Comparative safety and efficacy of short ragweed extracts differing in potency and composition in the treatment of fall hay fever. Use of allergenically bioequivalent doses by parallel line bioassay to evaluate comparative safety and efficacy
181. Serum sickness triggered by anaphylaxis: a complication of immunotherapy
182. Oral immunotherapy with grass pollen in enterosoluble capsules. A prospective study of the clinical and immunological response
183. Immunotherapy in allergy to dog: immunologic and clinical findings of a double‐blind study
184. Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy
185. Immunotherapy for aeroallergen disease
186. Immunotherapy for cat asthma
187. Efficacy of grass‐maize pollen oral immunotherapy in patients with seasonal hay fever. A double‐blind study
188. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs
189. A prospective national study of the safety of immunotherapy
190. Liposomes for allergy immunotherapy
191. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma
192. Immunotherapy, yesterday's treatment
193. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite
194. Preseasonal intranasal immunotherapy with nebulized short ragweed extract
195. Allergen‐controlled study of intranasal immunotherapy for ragweed hay fever
196. Immunotherapy with partially purified and standardized tree pollen extracts
197. Immunogenicity in guinea pigs and tolerance in grass‐pollen sensitive volunteers of enteric‐coated grass pollen allergens
198. Nonspecific immunotherapy and specific hyposensitization in severe atopic dermatitis
199. Is it possible to predict the clinical effect of immunotherapy?
200. Side effects during immunotherapy with purified grass pollen extracts
201. A prospective study on the safety of immunotherapy in children with severe asthma